Literature DB >> 12706707

DNA vaccines induce partial protection against Leishmania mexicana.

Eric Dumonteil1, Ramirez Sierra Maria Jesus, Escobedo Ortegon Javier, García Miss Maria del Rosario.   

Abstract

As part of an ongoing effort to develop a vaccine against Leishmania mexicana, we tested DNA vaccines encoding L. mexicana GP63, CPb, and LACK, and L. amazonensis GP46, to evaluate this strategy and define the best antigen candidates. Immune responses and vaccine efficacy were evaluated in BALB/c mice immunized with plasmid DNA encoding the different antigens. All four DNA vaccines induced Leishmania-specific humoral and lympho-proliferative immune responses. However, only mice immunized with VR1012-GP46, VR1012-GP63 and VR1012-CPb were partially protected against infection, as evidenced by reduced lesion size and parasite burden. Interestingly, immunization of mice with a mixture of these three plasmids further increased protection. Thus, plasmids encoding CPb, GP63 and GP46 represent good candidates for further development of DNA vaccines against L. mexicana.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706707     DOI: 10.1016/s0264-410x(02)00769-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.

Authors:  Blaise Dondji; Eva Pérez-Jimenez; Karen Goldsmith-Pestana; Mariano Esteban; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.

Authors:  Ingrid Aguilar-Be; Renata da Silva Zardo; Edilma Paraguai de Souza; Gulnara Patrícia Borja-Cabrera; Miguel Rosado-Vallado; Mirza Mut-Martin; Maria del Rosario García-Miss; Clarisa Beatriz Palatnik de Sousa; Eric Dumonteil
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice.

Authors:  Carmel B Stober; Uta G Lange; Mark T M Roberts; Antonio Alcami; Jenefer M Blackwell
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

Review 4.  Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.

Authors:  Malcolm S Duthie; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

5.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

6.  Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.

Authors:  Eduardo Fonseca Pinto; Roberta Olmo Pinheiro; Alice Rayol; Vicente Larraga; Bartira Rossi-Bergmann
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  Induction of murine immune responses by DNA encoding a 23-kDa antigen of Cryptosporidium parvum.

Authors:  Humphrey N Ehigiator; Pablo Romagnoli; Jeffrey W Priest; W Evan Secor; Jan R Mead
Journal:  Parasitol Res       Date:  2007-05-09       Impact factor: 2.289

8.  Nitric oxide production by Peromyscus yucatanicus (Rodentia) infected with Leishmania (Leishmania) mexicana.

Authors:  Elsy Nalleli Loría-Cervera; Erika Ivett Sosa-Bibiano; Liliana Estefanía Villanueva-Lizama; Nicole Raymonde Van Wynsberghe; Silvia Beatriz Canto-Lara; José Luis Batún-Cutz; Fernando José Andrade-Narváez
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-04       Impact factor: 2.743

9.  Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.

Authors:  Rhea N Coler; Yasuyuki Goto; Lisa Bogatzki; Vanitha Raman; Steven G Reed
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.